Skip to main content
Navigate back to homepage
Open search bar.
Open main navigation menu

Main navigation

  • Study
    UCL Portico statue
    Study at UCL

    Being a student at UCL is about so much more than just acquiring knowledge. Studying here gives you the opportunity to realise your potential as an individual, and the skills and tools to thrive.

    • Undergraduate courses
    • Graduate courses
    • Short courses
    • Study abroad
    • Centre for Languages & International Education
  • Research
    Tree-of-Life-MehmetDavrandi-UCL-EastmanDentalInstitute-042_2017-18-800x500-withborder (1)
    Research at UCL

    Find out more about what makes UCL research world-leading, how to access UCL expertise, and teams in the Office of the Vice-Provost (Research, Innovation and Global Engagement).

    • Engage with us
    • Explore our Research
    • Initiatives and networks
    • Research news
  • Engage
    UCL Print room
    Engage with UCL

    Discover the many ways you can connect with UCL, and how we work with industry, government and not-for-profit organisations to tackle tough challenges.

    • Alumni
    • Business partnerships and collaboration
    • Global engagement
    • News and Media relations
    • Public Policy
    • Schools and priority groups
    • Visit us
  • About
    UCL welcome quad
    About UCL

    Founded in 1826 in the heart of London, UCL is London's leading multidisciplinary university, with more than 16,000 staff and 50,000 students from 150 different countries.

    • Who we are
    • Faculties
    • Governance
    • President and Provost
    • Strategy
  • Active parent page: Brain Sciences
    • Study
    • Research
    • About the Faculty
    • Institutes and Divisions
    • Active parent page: News and Events
    • Contact

European trial for amyotrophic lateral sclerosis reports positive top line results

A large study which UCL and UCLH are part of suggests a type of immunotherapy can improve survival rates in amyotrophic lateral sclerosis (ALS). Results indicate that for patients with less aggressive disease progression, risk of death could be reduced by 40%

7 December 2022

Breadcrumb trail

  • Brain Sciences
  • News and Events

Faculty menu

  • Current page: Faculty news
  • Events

The MIROCALS study (Modifying Immune Response and Outcomes in ALS) is looking at use of low dose interleukin 2 (id IL2) in ALS – a condition that attacks the nerves that control movement so muscles no longer work. It kills a third of people within a year and currently there is no cure.

At UCL and UCLH, the study was conducted at the NIHR UCLH Clinical Research Facility (CRF) Leonard Wolfson Experimental Neurology Centre (LWENC), the National Hospital for Neurology and Neurosurgery and UCL Queen Square Institute of Neurology, with Dr Nik Sharma as local Principal Investigator.

Top line results from the study were presented today by Dr Gilbert Bensimon, from the Centre Hospitalier Universitaire de Nîmes, on the opening day of the Motor Neurone Disease Association’s 33rd International Symposium on ALS/MND. The trial, involving research groups in the UK, France, Italy and Sweden, tested whether low doses of IL2 can alter aspects of the immune system associated with inflammation in the central nervous system, which is believed to play an important role in the speed at which ALS progresses.

220 people with ALS recruited shortly after diagnosis were randomised in equal proportion to receive low dose IL2 or placebo for 18 months. The primary measurement was the mortality rate. The study found the treatment was well tolerated, with adverse events recorded as mostly mild to moderate, occurring across both active treatment and placebo arms. The study confirmed results of a previous pilot study which showed that IL2 decreases inflammatory markers in the blood.

Initial analysis of survival showed a small (19%) but not statistically significant decrease in the risk of death at 21 months. However, further analysis showed a larger and statistically significant treatment effect on survival. This effect was not present in participants who had aggressive, fast progressing disease – around 20% of patients. But for around 80% of participants with less aggressive disease progression, there was a significant decrease in the risk of death by over 40%.

The severity of disease progression was highly linked to levels of a substance found in cerebrospinal fluid called phosphorylated neurofilament heavy chain (CSF pNFH) – the primary biomarker used in the study.  The results provide encouraging evidence in support of altering ALS disease progression through immune system modification and approaches addressing neuroinflammation. 

  Prof Andrea Malaspina, of the UCL Queen Square Motor Neuron Disease Centre, Principal Investigator of the international MIROCALS consortium, commented: "This is a significant development in the right direction for individuals living with ALS. I thank all patients, Dr Nik Sharma and the NIHR UCLH CRF Team. Their work has been major contribution to the development of novel therapeutics for ALS."
 Professor Vincenzo Libri, Director of the NIHR UCLH CRF and LWENC said: “We are proud at the CRF to have been part of this research which represents a real step forward in the possible treatment of ALS, a neurodegenerative disease with such a huge unmet need. I want to thank all patients who were part of this research and our staff at the CRF who delivered it.”

Dr Bensimon, lead investigator and project co-ordinator, said: “MIROCALS is the first large scale randomised placebo-controlled trial to demonstrate ‘proof of principle’ in relation to IL2 with the potential to translate into clinical benefit for people living with this devastating condition.”
Professor Nigel Leigh, co-lead and chief trial investigator, of Brighton and Sussex Medical School, said: “There remain many questions to address, but the wealth of data and samples accumulated are supporting ongoing research to better understand the factors that drive ALS disease progression. These will hopefully open the door to new therapeutic avenues and more personalised approaches to treatment, to deliver even more positive outcomes in future trials.
Dr Brian Dickie, Director of Research for the UK-based Motor Neurone Disease Association, said: “ALS is a relentlessly progressive and devastating disease that robs people of their independence and ultimately their lives. Taking part in clinical trials requires a significant commitment from people with ALS and we are so grateful of everyone who volunteered for this important and ground-breaking study.”

Links

  • Full press release from the Motor Neurone Disease Association
  • Motor Neurone Disease Association research blog
  • MIROCALS 
  • Queen Square Motor Neuron Disease Centre, UCL Queen Square Institute of Neurology
  • Professor Malaspina's academic profile
  • Professor Libri's academic profile

Source 

  • UCLH Biomedical Research Centre

UCL footer

Visit

  • Bloomsbury Theatre and Studio
  • Library, Museums and Collections
  • UCL Maps
  • UCL Shop
  • Contact UCL

Students

  • Accommodation
  • Current Students
  • Moodle
  • Students' Union

Staff

  • Inside UCL
  • Staff Intranet
  • Work at UCL
  • Human Resources

UCL social media menu

  • Link to Soundcloud
  • Link to Flickr
  • Link to TikTok
  • Link to Youtube
  • Link to Instagram
  • Link to Facebook
  • Link to Twitter

University College London, Gower Street, London, WC1E 6BT

Tel: +44 (0) 20 7679 2000

© 2025 UCL

Essential

  • Disclaimer
  • Freedom of Information
  • Accessibility
  • Cookies
  • Privacy
  • Slavery statement
  • Log in